Kala Pharmaceuticals, Inc. (KALA)
USD 3.75
(0.81%)
USD 3.75
(0.81%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -17.35 USD | -11466.67% |
| 2022 | -0.15 USD | 99.87% |
| 2021 | -116.79 USD | -9.23% |
| 2020 | -106.92 USD | 28.27% |
| 2019 | -149.06 USD | -19.51% |
| 2018 | -124.73 USD | 59.2% |
| 2017 | -305.74 USD | -218.65% |
| 2016 | -95.95 USD | -98.82% |
| 2015 | -48.26 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -3.16 USD | 24.76% |
| 2024 Q1 | -4.20 USD | -32.08% |
| 2023 Q4 | -3.18 USD | 6.74% |
| 2023 FY | - USD | -11466.67% |
| 2023 Q1 | -9.04 USD | -5.12% |
| 2023 Q2 | -4.36 USD | 51.77% |
| 2023 Q3 | -3.41 USD | 21.79% |
| 2022 Q4 | -8.60 USD | -144.35% |
| 2022 FY | - USD | 99.87% |
| 2022 Q2 | -18.50 USD | 17.45% |
| 2022 Q3 | 19.39 USD | 204.81% |
| 2022 Q1 | -22.41 USD | 38.7% |
| 2021 Q1 | -24.66 USD | 9.77% |
| 2021 Q3 | -21.62 USD | 23.52% |
| 2021 Q4 | -36.56 USD | -69.1% |
| 2021 FY | - USD | -9.23% |
| 2021 Q2 | -28.27 USD | -14.64% |
| 2020 FY | - USD | 28.27% |
| 2020 Q4 | -27.33 USD | -9.58% |
| 2020 Q3 | -24.94 USD | -19.22% |
| 2020 Q2 | -20.92 USD | 22.32% |
| 2020 Q1 | -26.93 USD | 14.4% |
| 2019 Q3 | -33.91 USD | 3.56% |
| 2019 Q2 | -35.16 USD | 6.16% |
| 2019 Q1 | -37.47 USD | 1.24% |
| 2019 FY | - USD | -19.51% |
| 2019 Q4 | -31.46 USD | 7.23% |
| 2018 Q2 | -29.76 USD | -29.28% |
| 2018 Q3 | -31.71 USD | -6.55% |
| 2018 FY | - USD | 59.2% |
| 2018 Q1 | -23.02 USD | 0.04% |
| 2018 Q4 | -37.94 USD | -19.65% |
| 2017 Q4 | -23.03 USD | 18.36% |
| 2017 Q1 | -28.23 USD | -16.22% |
| 2017 Q2 | -23.59 USD | 16.44% |
| 2017 Q3 | -28.21 USD | -19.58% |
| 2017 FY | - USD | -218.65% |
| 2016 Q4 | -24.29 USD | 13.16% |
| 2016 Q2 | -28.50 USD | -87.62% |
| 2016 FY | - USD | -98.82% |
| 2016 Q1 | -15.19 USD | 0.0% |
| 2016 Q3 | -27.97 USD | 1.86% |
| 2015 FY | - USD | 0.0% |